Are Dipeptidyl Peptidase (DPP)-4 Inhibitors Safe in Patients with Heart Failure?

Significant focus has been placed on the cardiovascular effects of various treatment options for type 2 diabetes. One topic of concern is the risk of heart failure (HF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors. This piece reviews the literature on DDP-4 inhibitor therapy and the risk of HF and HF hospitalization. Suggestions on how to apply the literature to practice are also provided.

Flipping Your Rotation (Part 1 of 2): The Fundamentals

In the health care field, learners are expected to complete experiential training (often called rotations or clerkships) to develop clinical skills. However, encouraging learners to apply concepts learned in the classroom often requires a lot of dedicated teaching. As a preceptor, do you find it challenging to make time to teach students because of your other obligations? In this two-part series, we’ll cover strategies to help you engage students on rotation while maximizing time for other activities using the flipped classroom model. In Part 1, we’ll describe the fundamentals of the flipped classroom and explain its benefits and challenges. In Part 2, we’ll cover how the flipped classroom can be applied to experiential learning.

Digoxin defended: why make a SHIFT to ivabradine?

Following publication of the 2016 update to the American College of Cardiology Foundation / American Heart Association guidelines for the management of patients with heart failure, there’s been growing interest in the use of ivabradine, particularly to reduce the risk of rehospitalization for heart failure. But haven’t we had access to an agent that prevents heart failure rehospitalizations for a long time now? In this entry, we’ll explore how digoxin can fill an important niche in the management of patients with heart failure who remain at high risk for readmission despite optimal guideline-directed medical therapy.

Which Thiazide-Type Diuretic Should be First-Line in Patients with Hypertension?

The Eighth National Joint Committee recommends a thiazide-type diuretic as one of the first line treatment options for patients with hypertension. However, there is substantial evidence to support the use of a thiazide-like diuretic (e.g., chlorthalidone) over a thiazide diuretic (e.g., hydrochlorothiazide or HCTZ). In this piece, we review the data on why thiazide-like agents should be preferred in this setting.